Review advisory group

An international advisory group provides expertise to the Review. Its current members are:

Dr Ren Minghui
Ren Minghui is currently the Director-General for International Cooperation, China National Health and Family Planning. He served on the Executive Board of WHO and the Board of Global Fund to Fight HIV/AIDS, TB and Malaria for many years. Dr. Ren actively participates in meetings, consultations, country programs and activities organized by UNAIDS and GAVI. Ren Minghui is in charge of Chinese bilateral health cooperation mechanisms in China with various governmental and private sector partners, including USA, UK, Canada, Australia, Russia and the Gates Foundation, for their program on emerging infectious diseases prevention & control, as well as health policy. Ren Minghui holds a PhD in Health Policy and Management from Peking University, and a Master of Public Health from Harvard School of Public Health. Recently, Dr Ren has engaged in promoting health cooperation in BRICS countries, and China-African countries, and published several articles on global health development.

Nana Kuo
Nana Taona Kuo is a development economist and public policy specialist by training, with over 14 years’ experience in Global Health, rural development, HIV and public health, particularly in Asia and the Pacific.  She is currently the Senior Manager of the Every Woman Every Child Health Team in the Executive Office of the UN Secretary-General, United Nations, New York. Every Woman Every Child is a special imitative of UN Secretary-General, Ban Ki-moon, launched in 2010, is an unprecedented global movement that mobilizes and intensifies international and national action by governments, the UN, civil society, private sector and multilaterals to save and improve the lives of millions of women and children around the world.
Prior to joining the UN Secretary-General’s Office, Taona Kuo was the UNAIDS Country Coordinator a.i in China and spent over 5 years working in China with UNAIDS. She coordinated the China UN system support to the 4th International Roundtable on China-Africa Health Cooperation, the first Roundtable to be held in Africa in Botswana, May 2013. She also provided inputs to the first Ministerial Forum of China-Africa Health Development under the Forum for China-Africa Cooperation (FOCAC) held in August 2013, which recognized the role of international cooperation partners.

Dr Sanjeev Chaudhry
Dr. Sanjeev K Chaudhry is an accomplished management professional, a business turnaround specialist, author and researcher. He is presently Managing Director of SRL Limited, India (Formerly SRL Ranbaxy Limited) , Chairman of CSC Nutrigenomics Pte Limited, Singapore and Chairman of SRL Reference Laboratories, Nepal. He also serves on the Board of Directors of several companies and institutions in India and abroad.
SRL is India’s largest and world’s leading Healthcare Diagnostics Company. The company runs a network of over 250 Pathology Laboratories and Radiology Centers in India and serves over ten million people annually.
He was the South Asia head of DuPont Solae until June 2006, a position he held for eleven years. Prior to that he served as Chairman & Managing Director of Modern Food Industries and was the youngest person to head a Government of India company. He was also the first CEO of NatOleo Sdn Bhd Malaysia one of world’s largest producers of Oleochemicals.
He has a Ph.D in Business Administration from Columbia University, United States and holds a university record for Masters in Economics at Punjab University, Chandigarh. Sanjeev lives in New Delhi, India with his wife and children.

Michael W. Bonney
Michael W. Bonney became Chair of the Board of Directors at Cubist on January 1, 2015. Cubist was acquired by Merck late in January of 2015. Prior to this, he served as Chief Executive Officer and as a member of the Board of Directors from June 2003 to December 2014. From 2003 to 2012, Mr. Bonney served as President and Chief Executive Officer. From January 2002 to June 2003, he served as President and Chief Operating Officer. From 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., a biopharmaceutical company, including Vice President, Sales and Marketing from 1999 to 2001. While at Biogen, Mr. Bonney built that company’s first commercial infrastructure for the launch of Avonex. Prior to that, Mr. Bonney held various positions of increasing responsibility in sales, marketing, operations and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as National Business Director. Mr. Bonney received a B.A. in Economics from Bates College. Mr. Bonney is a Director of Celgene, Inc, and Alnylam Pharmaceuticals Inc, both biopharmaceutical companies; a Trustee of H&Q Healthcare Investors, H&Q Life Sciences Investors Funds and TEKLA Health Care Fund; and Chairman of the Board of Trustees of Bates College. He is an advisor to other private biopharmaceutical companies. Mike is a former board member of the Biotechnology Industry Organization, or BIO, Health Section Governing Body, and former director of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Dr Steven Solomon 
Dr. Steven L. Solomon is an infectious disease physician and expert in public health policy and currently a principal of Global Public Health Consulting.   Prior to retiring from government service in May 2015, Dr. Solomon held several executive positions at the United States Centers for Disease Control and Prevention, most recently as Director of the Office of Antimicrobial Resistance.  He has developed and led research, program and policy initiatives in clinical infectious diseases, prevention of healthcare-associated infections, patient safety, disease surveillance and monitoring, public health informatics and health communications.  His current focus is on developing innovative strategies for preventing, controlling and treating antimicrobial resistant infections.  In his last post at CDC, he served as managing co-chair of the US Federal Interagency Task Force on Antimicrobial Resistance and the director of the Secretariat of the Transatlantic Task Force on Antimicrobial Resistance.  He earned his BA from Rutgers University and his MD from Tufts University. He is a fellow of the American College of Physicians and is board-certified in internal medicine, infectious diseases and preventive medicine.  Dr. Solomon retired from the United States Public Health Service at the rank of Rear Admiral.  

New Advisory Group Members

We are delighted that three new members have joined our informal advisory group from India, Brazil and South Africa.

Dr Yusuf K. Hamied
Dr. Yusuf K. Hamied is the non-executive chairman of Cipla, having grown the company as it's managing director into one of the largest multinational generic drug companies with headquarters in India, the EU and in the United States. Dr. Hamied is a leading scientist and businessman though he is best known for his humanitarian role in making AIDS medicines available and affordable in Africa by reducing the price of a three drug combination to below a $1 a day, when the prevailing price of the combined three drugs was US$ 12,000 per patient per year. He has been conferred with numerous awards including the Padma Bhushan, a civilian honour from the Government of India in 2005. He is also a Fellow of Christ College, Cambridge, an Honorary Doctorate of Cambridge University in 2014 and an Honorary Fellow of the Royal Society of Chemistry in 2012. He obtained his Ph.D. under the Nobel Laureate, Lord Alexander Todd from Cambridge University in 1960.

Dr Milton O. Moraes 
Dr. Milton Ozório Moraes is a researcher at Oswaldo Cruz Foundation (FIOCRUZ), the reference Institution in Public Health and biomedical research in Brazil. He is Dean of Graduate Programs at FIOCRUZ, head of Leprosy Laboratory and Associate Professor at the State University of Rio de Janeiro. His research interests are focused on the development of novel, specific and rapid tools for diagnostics and surveillance of tuberculosis and leprosy (among other infectious diseases) using functional genomics and genetic epidemiology.  He is also part of Brazilian and international research networks in different countries such as Mozambique, India, Swiss, Canada, France, Holland, and USA. He is now responsible for capacity building and training human resources programs in Brazil devoted to strategic issues such as development of training programs for diagnostic and treatment of infectious diseases at FIOCRUZ. Dr Moraes has been formally trained in the molecular biology and immunology of leprosy and received his PhD in Brazil in 2000. 

Prof. Eric Goosby 
Eric Goosby has dedicated his professional life to fighting HIV/AIDS from treating patients to running international programs. After serving four years in the US State Department as Ambassador-at-Large and US Global AIDS Coordinator, overseeing the implementation of the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the Office of Global Health Diplomacy, Ambassador Goosby returned to the University of California, San Francisco where he is Professor of Medicine and Director for Global Health Delivery and Diplomacy. 
As CEO and Chief Medical Officer of Pangaea Global AIDS Foundation, 2001-2009, he played a key role in the development and implementation of HIV/AIDS national treatment scale-up plans in South Africa, Rwanda, China and Ukraine.
Dr. Goosby was recently appointed by UN Secretary-General Ban Ki-moon as the UN Special Envoy on Tuberculosis (TB). In his capacity as Special Envoy, Dr. Goosby works toward raising the profile of the fight against TB and promoting the adoption, financing and implementation of the World Health Organisation’s global End TB Strategy after 2015.